Modified glasgow prognostic score predicts survival among advanced non-small cell lung carcinoma patients treated with anti-PD1 agents

• Type: Article in International Scientific Journal
• Date: 2021

Authors

Cláudia Freitas (Author) FMUP; Maria Jacob (Author) FMUP; Nuno Tavares (Author) Other; Natália Cruz-Martins (Author) FMDUP; Maria da Conceição Moura (Author) FMUP; David Araújo (Author) FMUP; Hélder Novais-Bastos (Author) FMUP; Vanessa Santos (Author) Other; Gabriela Fernandes (Author) FMUP; Adriana Magalhães (Author) Other; Venceslau Hespanhol (Author) FMUP; Henrique Queiroga (Author) FMUP

Journal

Title: Anti-Cancer Drugs

Vol. 32 No. 5

Pages: 567-574

ISSN: 0959-4973

Publisher: Wolters Kluwer Health

Indexing

ISI Web of Knowledge - 2 Citations

Scopus - 2 Citations

Other information

Authenticus ID: P-00T-SK5

DOI: 10.1097/cad.0000000000001060

Abstract (EN): Immune checkpoint inhibitors were approved for advanced nonsmall cell lung cancer (NSCLC) treatment. Despite improved survival, not all patients benefit from these agents. Here, the prognostic impact of pretreatment modified Glasgow Prognostic Score (mGPS) and neutrophil-to-lymphocyte ratio (NLR) was assessed. From 77 patients included, 83.2% received at least one prior systemic therapy. Immune-related adverse events (irAE) occurred in 20 patients. A lower mGPS was associated with higher median overall survival (OS), and a lower Eastern Cooperative Oncology Group (ECOG), irAE and fewer metastatic sites with better survival. A trend towards greater OS and progression-free survival (PFS) was stated among patients with NLR 2 with worse OS and irAE with better survival. Pretreatment mGPS seems to be useful for predicting survival among advanced NSCLC patients treated with anti-programmed cell death 1 drugs, with ECOG performance status, irAE occurrence, and number of metastatic sites acting as survival predictors.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 8